Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and…
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $45
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $40 to $45.